Large pharmaceutical companies are prioritizing strategic bolt-on acquisitions over megadeals. These transactions typically range in the low-single-digit billions.
Firms are seeking to replenish drug pipelines before major patents expire. This shift follows mixed results from previous blockbuster mergers and a move toward disciplined pricing.
The trend benefits the biotech industry by distributing capital across a wider range of smaller firms. M&A activity in 2026 is moving at a record pace for deals valued above $1 billion. No single acquisition has exceeded $10 billion this year. These dynamics have caused biotech stocks to outperform the broader market in 2026.